AstraZeneca

News

NICE backs AZ’s Forxiga for heart failure

Just a few weeks after its EU approval for heart failure, AstraZeneca’s Forxiga has been backed by NICE for this use by the NHS in England and Wales.

News

AZ, Amgen’s asthma hope tezepelumab flunks phase 3 trial

AstraZeneca and Amgen looked on course to cruise to approval of their severe asthma drug tezepelumab with a pair of positive clinical trials, but the failure of a third threatens to derail

News

AstraZeneca's (AZ) Tagrisso (osimertinib)

AZ's Tagrisso gets new early lung cancer use in US

AstraZeneca’s Tagrisso (osimertinib) has been approved by the FDA in a new lung cancer indication that extends its use to a group of patients with early-stage disease.

News

Radiology technician examens mammography test on location

MacroGenics' HER2 breast cancer drug Margenza approved in US

MacroGenics’ HER2-targeted breast cancer drug Margenza has been approved by the FDA, challenging several recently approved drugs with a narrow efficacy edge over Roche’s Herceptin in data g

News

Daiichi Sankyo, AZ close on EU approval of Enhertu for breas...

Daiichi Sankyo and AstraZeneca could be just weeks away from an EU approval for their antib

News

Alexion finally has a buyer – and it's AstraZeneca with $39b...

Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and that was a good call – AstraZeneca has just swooped in with $39 billion cash-

NICE backs AZ’s Forxiga for heart failure

AZ, Amgen’s asthma hope tezepelumab flunks phase 3 trial

AZ's Tagrisso gets new early lung cancer use in US

MacroGenics' HER2 breast cancer drug Margenza approved in US

Daiichi Sankyo, AZ close on EU approval of Enhertu for breas...

Alexion finally has a buyer – and it's AstraZeneca with $39b...

Making direct-to-patient work, with Matt Wadyka

Using AI-driven synthetic personas to take your insights fur...

AstraZeneca

Editor's Picks